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An intravenous administration of a high-dose Ag can induce immune tolerance and 
suppress the immune response, but the mechanism remains unclear. We recently 
proved that a combined intravenous administration of OVA and IL-2-anti-IL-2 Ab 
immune complexes (IL-2 ICs) efficiently expands OVA-specific Treg cells in the 
thymus and induces their migration into peripheral blood, by using OVA-specific T-cell 
receptor Tg-expressing DO11.10 mice. Here, we demonstrate that the expanded 
OVA-specific Treg cells rapidly move into the air pouch after OVA injection in 
DO11.10 mice. The migration was inhibited by blocking the axis of a chemokine 
receptor, CCR2. Moreover, prior treatment with OVA and IL-2 ICs enhanced 
OVA-specific Treg-cell migration and inhibited OVA-induced delayed-type 
hypersensitivity (DTH) reactions in the skin of BM chimeric mice with 15 % of T cells 
expressing OVA-specific T-cell receptor. Blocking the CCR2 axis reversed this 
suppression of DTH in these mice. Furthermore, prior treatment with OVA and IL-2 
ICs effectively reduced DTH reactions even in WT mice possessing only a very small 
population of OVA-specific T cells. Thus, the treatment with Ag and IL-2 ICs can 
efficiently expand Ag-specific Treg cells with the capacity to migrate and reduce 






Recognition of a foreign substance initiates adaptive immunity, thereby generating 
Ag-specific T cells and Abs. The immune system can recognize autologous molecules 
as well as exogenous ones, but the immune reaction against an autologous Ag can 
cause a deleterious condition, the autoimmune response. The thymus has a crucial role 
in the prevention of autoimmune responses by educating a T-cell precursor, the 
thymocyte, to become unresponsive to autologous Ags. This process, called 
intrathymic education, consists of two processes, negative selection and differentiation 
of naturally occurring Treg (nTreg) cells. Negative selection eliminates thymocytes, 
which can recognize autologous Ags with high affinity, while nTreg can inhibit the 
effecter T (Teff) cell response to autologous Ags in an Ag-specific manner. 
The mode of immune response can differ depending on the dose of Ag, the route of 
administration, and the presence of adjuvant. Subcutaneous or dermal injection of a 
protein emulsified in adjuvant can activate T cells [1], whereas oral exposure to an Ag 
can induce tolerance [2]. Moreover, an intravenous injection of a high-dose Ag can 
induce Ag-specific immune tolerance [3-5] and can prevent autoimmune diseases in 
mice such as type 1 diabetes mellitus [6] or EAE [4]. Although intrathymic education 
is generally vital to induce immune tolerance, the role of the thymus in immune 
tolerance induced by an intravenous injection of a high-dose Ag needs further 
clarification. 
IL-2 is one of the most important cytokines for Treg-cell development and survival 
[7]. Moreover, Webster et. al. [8] observed that in vivo administration of IL-2 immune 
complexes (ICs) can induce a marked increase in Treg cells in many organs, including 
the liver and gut as well as the spleen and LNs, with a modest increase in Treg cells in 
the thymus. Furthermore, pre-treatment with IL-2 ICs rendered mice resistant to 




We previously demonstrated that thymic CD11c+CD11b+CD8α-Sirpα+ conventional 
DCs (cDCs) are preferentially localized in an interlobular vascular-rich region and that 
they can selectively capture blood-circulating Ag and induce Ag-specific Treg-cell 
generation, thereby inducing immune tolerance in the thymus [9, 10]. We therefore 
postulated that the combined intravenous injection of an Ag and IL-2 ICs could expand 
Ag-specific Treg cells with a capacity to migrate to the Ag-containing site, thereby 
reducing Ag-specific immune responses. In order to prove this assumption, we 
examined the effects of combined intravenous injection of OVA and IL-2 ICs on an 
OVA-induced DTH reaction in the skin. We provide here definitive evidence indicating 
that the treatment generated Ag-specific Treg cells in thymus which could migrate 






Ag-specific Treg cells preferentially migrate to an Ag-containing site. 
We first examined whether Ag-specific Treg cells could migrate to the Ag injection site. 
In order to address this point, we repeated intravenous OVA injection to DO11.10 mice 
twice before OVA administration into air pouch (Figure 1A). This resulted in the rapid 
appearance of KJ1-26highFoxp3- Teff cells in the air pouch within 12 h after OVA 
administration (Figure 1B). Subsequently, KJ1-26highFoxp3+ Treg cells accumulated in 
the air pouch more than 24 h after OVA injection, comprising more than 20% of the 
total KJ1-26high cells (Figure 1B). The administration of BSA into the air pouch failed 
to induce KJ1-26highFoxp3+ Treg-cell accumulation (Figure 1C), suggesting that a 
localized Ag at the induced inflammatory site can attract Ag-specific Treg cells. In 
order to test this assumption, we collected lymphocytes from DO11.10 mice either 
immunized twice with OVA or non-immunized. These cells were labeled with 
carboxyfluorescein diacetate succinimidyl ester (CFSE) and administered to WT mice 
(Supporting Information Figure 1A). Subsequent administration of OVA into air pouch 
of such recipient mice induced the accumulation of CFSE-labeled immunized 
KJ1-26highFoxp3+ Treg cells but not non-immunized cells in the air pouch (Figure 1D). 
Furthermore, the in vivo primed Treg cells, in which CFSE signal was diluted by the 
cell division, mainly accumulated in the air pouch (Figure 1D). Consequently, 
Ag-specific Treg cells can migrate to the site containing the Ag. 
 
Intravenously administered Ag induces intrathymic Treg cells and their migration 
into the periphery 
We previously demonstrated that an intravenous injection of an Ag can induce 
differentiation of Ag-specific Treg cells in the thymus [10]. Untreated thymus 
contained a small number of both KJ1-26lowFoxp3+ and KJ1-26highFoxp3+ cells 
(Supporting Information Figure 2). Following intravenous OVA injection, 
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KJ1-26highFoxp3+ but not KJ1-26highFoxp3- thymocytes increased (Figure 2A, 
Supporting Information Figure 2, and 3). However, the KJ1-26highFoxp3+ thymocyte 
number decreased at 5 days after OVA injection (Figure 2A). Concomitantly, 
KJ1-26highFoxp3+ Treg cells appeared in peripheral blood 5 days after OVA injection 
(Figure 2B). The increase in KJ1-26highFoxp3+ Treg cells in peripheral blood was 
reduced by removal of the thymus but not spleen (Figure 2C). Moreover, intravenous 
OVA injection increased Helios+Foxp3+ Treg cells in the thymus, and to a lower extent, 
in the spleen (Figure 2D). Concomitantly, most Foxp3+ cells in peripheral blood 
expressed Helios (Figure 2E). Finally, we obtained lymphocytes from DO11.10 mice, 
either immunized with OVA or non-immunized, and transferred them into the air 
pouch-bearing WT mice (Supporting Information Figure 1B). WT mice, which 
received non-immunized DO11.10 lymphocytes, were subsequently immunized with 
OVA to induce Treg cells mainly in the periphery. OVA injection into the air pouch led 
to a higher proportion of Foxp3+ Treg cells among KJ1-26high cells at the air pouch, in 
the mice receiving the immunized lymphocytes than in the mice receiving 
unimmunized lymphocytes and subsequent intravenous OVA injection (Figure 2F). 
Thus, Ag-specific Treg cells, which were generated in the thymus, could migrate into 
the antigen site more efficiently than peripherally-induced Treg cells. 
 
Ag-specific Treg cells migrate to the air pouch in a CCR2-dependent manner 
The selective migration of Ag-specific Treg cells prompted us to investigate the 
contribution of chemokines, which can exhibit chemotactic activities on a selected set 
of leukocytes with their receptors [11-13]. Flow cytometry (FCM) analysis 
demonstrated an enhanced expression of several chemokine receptors including CCR2, 
CCR4, CCR5, and CXCR4 on Ag-specific Treg cells infiltrating in Ag-injected air 
pouch, compared with Teff cells (Figure 3A). Of particular interest is that most 
Ag-specific Treg cells in the OVA-injected air pouch expressed CCR2, and that the 
expression level was higher than that in the draining LN (dLN). These observations 
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suggested the involvement of the ligands for these receptors in the migration of 
Ag-specific Foxp3+ Treg cells into the air pouch. The administration of OVA into the 
air pouch consistently induced increases in the contents of CCL2, the ligand for CCR2, 
CCL17 and CCL22, the ligands for CCR4, and CCL5 (RANTES), the ligand for CCR5 
(Supporting Information Figure 4), but not CXCL12, the ligand for CXCR4 (data not 
shown). In order to prove the roles of these chemokines, we blocked the axes of these 
chemokines. Consistent with the previous report [14, 15], anti-CCL17 and anti-CCL22 
neutralizing Abs reduced the numbers of KJ1-26high Treg cells migrating into the 
OVA-injected air pouch with no effect on the proportion of KJ1-26high Treg cells in the 
draining lymph node (Supporting Information Figure 5). Accumulating evidence 
identifies truncated RANTES (tRANTES) as a potent antagonistic protein against 
CCR5 [16]. Moreover, in vivo transfection of tRANTES expression vector (Supporting 
Information Figure 6) can sustain serum tRANTES levels sufficient to block 
CCR5-mediated signals (our unpublished data). However, in vivo transfection of 
tRANTES-expressing vector failed to cause any significant changes in the number and 
proportion of KJ1-26high Treg cells, when compared with control vector (Supporting 
Information Figure 7). On the contrary, genetic ablation of CCR2 reduced the number 
and proportion of KJ1-26high Treg cells in the OVA-injected air pouch, but increased 
that of the dLN (Figure 3B). Because CCR2 is well-known as an essential factor for 
the monocyte and macrophage chemotaxis, it is possible that the reduced Treg-cell 
infiltration in CCR2-/- mice may be indirectly due to the less monocyte migration and 
reduction of infiltration. To exclude this possibility, lymphocytes from DO11.10 or 
DO11.10/CCR2-/- mice were transferred to WT mice bearing air pouch. OVA injection 
to the air pouch failed to attract the KJ1-26high Treg cells derived from 
DO11.10/CCR2-/- mice (Figure 3C). This proved that CCR2 expression on Treg cells is 
necessary for their migration to Ags. Thus, the expression of CCR2 can contribute to 




Induced Ag-specific Treg cells migrate into DTH site and suppress an excessive 
reaction 
We next examined the function of intravenously administered Ag-induced Treg cells in 
more pathologically relevant condition. In order to examine the immune suppressive 
activities of these Ag-specific Treg cells in the experimental DTH model, we first 
injected OVA into the footpad of DO11.10 mice after subcutaneous immunization with 
OVA emulsified in CFA (Figure 4A). However, the intractable and marked DTH 
response ensued due to a massive infiltration of KJ1-26high Teff cells into the injected 
footpad (our unpublished data). In order to circumvent the intractable DTH, we 
prepared BM chimeric mice using WT and DO11.10 mice to obtain mice with about 10 
to 15 % of T cells expressing DO11.10 clonotypic TCR (Supporting Information 
Figure 8). The resultant BM chimeric mice still exhibited a considerable DTH reaction 
as evidenced by an abundant leukocyte infiltration and an enhanced paw thickness 
(Figure 4B and 4C). Because the intravenous administration of OVA induced 
KJ1-26high Treg cell expansion (Figure 2A and 2B), IL-2 ICs was additionally 
administrated in combination with the intravenous OVA injection (Figure 4A). 
Consistent with the previous report [8], IL-2 ICs alone induced the expansion of 
polyclonal Vα2+ Treg cells, but not KJ1-26high Treg cells in peripheral blood, whereas 
the combined treatment with OVA and IL-2 ICs succeeded in expansion of KJ1-26high 
CD25+Foxp3+ Treg cells as well as polyclonal Treg cells (Figure 4D and Supporting 
Information Figure 9). The combined treatment with OVA and IL-2 ICs, but not that 
with OVA or IL-2 ICs alone diminished the DTH reaction as evidenced by decreased 
leukocyte infiltration and reduced paw thickness (Figure 4B and 4C). Likewise, the 
combined treatment with OVA and IL-2 ICs, but not that with OVA or IL-2 ICs alone 
increased the proportion of Foxp3+ cells in the inflammatory site (Figure 4E). Thus, in 
collaboration with IL-2 ICs, a prior intravenous injection of an Ag can expand 
Ag-specific Treg cells in the thymus and can induce their migration to the 




Reversion of Ag-IL-2 ICs-mediated suppression of DTH reaction by blocking 
CCR2 
We next examined whether Ag-specific Treg cells migrated into the Ag injection site to 
dampen DTH response in a CCR2-dependent manner, as observed on the air pouch 
model. Histological examination demonstrated that leukocytes infiltrated to the 
Ag-injected site to similar extents irrespective of the absence or the presence of CCR2 
gene (Figure 5A). However, Ag-IL-2 ICs suppressed leukocyte infiltration and paw 
thickness only in the presence of CCR2 gene (Figure 5A and 5B). Similarly, Treg-cell 
infiltration was enhanced by Ag-IL-2 ICs treatment only in the presence of CCR2 gene 
(Figure 5C). Likewise, neutralization of CCR4 ligands did abrogate the effects of 
Ag-IL-2 ICs treatment on DTH (Supporting Information Figure 10). Thus, Ag-specific 
Treg cells can utilize CCR2 and/or CCR4 to migrate into the Ag-localized site, thereby 
suppressing immune-mediated DTH reaction. 
 
Successful immune control by combined treatment of IL-2 ICs and Ag in DTH 
Finally, we examined whether the combined treatment with an Ag and IL-2 ICs can 
dampen DTH reaction even in WT mice, which do not possess monoclonal or 
oligoclonal T cells. When OVA-immunized WT mice were challenged with a 
subcutaneous OVA injection, the mice exhibited DTH reaction as evidenced by 
subcutaneous leukocyte infiltration and enhanced paw thickness (Figure 6A and 6B), 
although the magnitude of the reaction was weaker than that of BM chimeric mice 
(compare between Figures 4C and 6A). The prior combined intravenous administration 
with OVA and IL-2 ICs, but not that with IL-2 ICs or OVA alone, markedly reduced 
leukocyte infiltration and paw thickness (Figure 6A and 6B). Thus, the combined 
intravenous injection of an Ag and IL-2 ICs can reduce local immune response 
probably by inducing intrathymic differentiation of Ag-specific Treg cells and their 
migration into the site of the immune response under the control of chemokine 
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The administration of a high-dose Ag can induce immune tolerance by utilizing several 
mechanisms including depletion of Teff cells [4], induction of T-cell apoptosis in 
peripheral blood and thymus [5], suppression of Ig production [17], and expansion of 
Treg cells [18]. Here, we determined that an intravenous injection of a high-dose of Ag 
could efficiently expand Ag-specific Treg cells in a thymus-dependent manner and that 
the expansion could be further augmented by the additional administration of IL-2 ICs. 
Moreover, the expanded Ag-specific Treg cells preferentially migrated to the local 
injection site of Ag in a CCR2-dependent manner to prevent immune 
response-mediated DTH reactions. 
We previously demonstrated that thymic CD11c+CD11b+CD8-Sirpα+ cDCs are 
principally located in interlobular vascular-rich region of the thymic cortex and capture 
Ags from bloodstream [9] to induce Ag-specific Treg-cell generation [10]. Also under 
the present conditions, we observed that Ag-specific Treg cells appeared in the 
circulation after their transient intrathymic expansion. Evidence is accumulating to 
indicate that Treg cells can be generated in the spleen and LNs as well as the thymus. 
However, the removal of thymus but not spleen markedly reduced the increase in 
Ag-specific Treg-cell numbers in peripheral blood. Helios, a member of Ikaros 
transcription factor family, was once reported to be a marker of thymus-derived Treg 
cells. Intravenous Ag injection induced Helios expression on Ag-specific Treg cells in 
the thymus but not spleen. Thereafter, Ag-specific Treg cells in circulation started to 
express Helios. Several lines of evidence questioned the validity of Helios as a specific 
marker of thymus-derived Treg cells [19, 20]. However, intravenous Ag injection 
efficiently increased the Ag-specific Treg cells, which were generated in the thymus 
and to a lesser extent, ones converted in the periphery in the Ag containing site. Thus, 
it is probable that an intravenous Ag injection could induce Treg-cell generation in the 
thymus, although Treg-cell conversion from other T-cell populations in the periphery 
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can also contribute to a certain extent. 
Treg cells can be classified into two populations with distinct roles in immune 
tolerance, nTreg and induced Treg (iTreg) cells [21]. nTreg cells are generated in the 
thymus and can regulate mainly Th1 mediated-immune responses. On the contrary, 
iTreg cells are generated in the periphery outside the thymus and can control Th2 
mediated-response in mucosal tolerance [22]. We demonstrated that an intravenous Ag 
injection can induce Ag-specific Treg cells in the thymus. Thus, the intrathymically 
generated Treg cells can suppress DTH reaction, a typical Th1-mediated immune 
response upon reaching local Ag injection site. Several immunosuppressive maneuvers 
were developed by using iTreg cells, which were either expanded ex vivo [23] or 
differentiated in vitro [24]. On the contrary, we provided the first definitive evidence to 
indicate the immunosuppressive potential of intrathymic differentiated Ag-specific 
Treg cells, which are expanded independently of AIRE [25]. 
Treg cells can be an attractive target cell type for immune regulation. Webster et. al. 
demonstrated that the administration of IL-2 ICs selectively expanded Treg cells, and 
prevented the development of EAE and induced tolerance to MHC-incompatible 
pancreatic transplants [8]. We observed that treatment with IL-2 ICs alone expanded 
polyclonal Treg cells. However, the expansion of polyclonal Treg cells can cause 
generalized Ag-non-specific immune suppression [26-29]. Thus, the expansion of 
Ag-specific Treg cells is preferable to polyclonally expanded Treg cells to avoid 
generalized immune suppression. We showed that intravenous treatment with both an 
Ag and IL-2 ICs efficiently expanded Ag-specific Treg cells and subsequently 
suppressed DTH, whereas IL-2 ICs treatment alone could neither expand Ag-specific 
Treg cells nor suppress DTH. Thus, Ag-specific Treg cells can suppress specific 
immune responses such as DTH more efficiently than polyclonal Treg cells. 
Currently used immune-suppressive agents can inhibit immune reaction broadly and 
in an Ag-nonspecific manner. Thus, the use of Ag-specific Treg cells can be more 
effective and less harmful due to their selectivity. Moreover, the selectivity can be 
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further augmented by Ag-specific activation of Treg cells to exert their Ag-specific 
suppressive function in vivo [18]. Furthermore, once activated with an Ag, Ag-specific 
Treg cells can suppress additional immune reactions against other unrelated Ags in the 
organ exhibiting the specific Ag, resulting in organ-specific immune suppression 
against a broad range of Ags [30, 31].  We demonstrate that Ag-IL-2 ICs treatment 
can efficiently expand and activate Ag-specific Treg cells with the capacity to migrate 
to the organ containing a specific Ag. Thus, the present approach may be effective for 
organ-specific immune diseases, if pathogenic Ags or organ-specific Ags are 
definitively identified as in the case of contact dermatitis and GVHD. 
It is of interest that the expanded Ag-specific Treg cells preferentially migrated to 
the Ag injection site in the peripheral tissue, both in air pouch model and DTH reaction. 
Treg cells can migrate into various sites such as the tumor tissues, infected site and 
transplanted organs [15, 32-34], to suppress immune response to the tumor, infected 
tissues, or transplanted organs [27, 35]. Leukocyte migration is controlled by several 
factors and among them, chemokines have a crucial role. Leukocytes can migrate in 
response to the interaction between chemokine(s) expressed in the local site and the 
chemokine receptor(s) expressed by leukocytes [36-38]. Several lines of evidence 
indicate that Treg migration into the peripheral tissue is regulated by CD103, CCR2, 
CCR4 and CCR5 expression [15, 16, 34, 39, 40]. In particular, it is broadly known that 
CCR4 signaling plays an important role in Treg cells migration [15]. We demonstrated 
that most Ag-specific Treg cells expressed CCR2 as well as CCR4 and CCR5, and that 
Ag-injected air pouch contained abundant CCL2, the ligand for CCR2. These results 
suggest that CCR2 also have crucial roles in Treg cells migration. This notion is 
further supported by our present observation that blocking CCR2-mediated signaling 
reduced Ag-specific Treg cells migration into the Ag site. Moreover, blocking the 
receptors reversed Ag-IL-2 ICs-mediated suppression of DTH reactions. 
CCR2-mediated signals apparently have essential roles in Ag-specific Treg-cell 
migration into the Ag containing site in addition to CCR4-mediated signals. CCR2 
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signal is known to have a main role in migration of macrophage and dendritic cells to 
initiate inflammation. But, on the other hand, CCR2 could also contribute to 
Ag-specific Treg-cell migration to suppress immune reaction. Thus, CCR2-mediated 
signals can supplement the use of Ag-specific Treg cells to control DTH-related 




Materials and Methods 
Mice 
Female Balb/c mice were obtained from Charles River Japan (Yokohama, Japan) and 
designated as WT mice. DO11.10 mice expressing a Tg TCR that recognizes the 
OVA323–339 peptide in the context of I-Ad were maintained as heterozygotes. 
DO11.10/CCR2-/- mice were generated by mating DO11.10 and CCR2-deficient mice 
as previously described [9]. All mice were maintained in the animal facility of the 
Kanazawa University under specific pathogen-free conditions. All animal experiments 
were approved and performed according to the Guideline for the Care and Use of 
Laboratory Animals of Kanazawa University 
 
Reagents and Abs 
Rat anti-mouse DO11.10 clonotypic TCR (KJ1-26), Foxp3 (MF23) and IL-2 
(JES6-1A12) Abs were obtained from BD Bioscience (San Jose, CA). Rat anti-mouse 
CD4 (RM5-5) and Foxp3 (FJK-16s) Abs were obtained from eBioscience (San Diego, 
CA). Rat anti-mouse CD25 (PC61) and CD184/CXCR4 (TG12/CXCR4) Abs, and 
hamster anti-mouse CD194/CCR4 (2G12), Helios (22F6), and CD195/CCR5 
(HMCCR5) Abs were obtained from BioLegend (San Diego, CA). Recombinant mouse 
IL-2, and rat anti-mouse CCL17/TARC (110904), CCL22/MDC (158132), and 
CD192/CCR2 (475301) Abs were obtained from R&D systems (Minneapolis, MN). 
OVA and BSA were obtained from Sigma Aldrich (St. Louis, MO). 
 
Air pouch model (Figure 1A) 
Subcutaneous air pouches were prepared as described with some modifications [41]. 
Briefly, 5 ml of air was subcutaneously injected to dorsal surface of WT or DO11.10 
mice. 2 mg of OVA dissolved in 200 μL of PBS was injected intravenously twice, one 
and two days after the air injection. 3 ml of air was additionally injected into the air 
pouch on Day 3. On Day 4, 100 μg of OVA in 1 ml of PBS was injected into the air 
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pouch. At the indicated time points after the last OVA injection into the air pouch, the 
cells in the air pouch were recovered by washing the air pouch with 1 ml of cold PBS. 
The obtained fluid samples were centrifuged to obtain the supernatants and the cell 
suspensions. The supernatants were used for the determination of chemokines by 
ELISA while the cell suspensions were used for cell surface marker analysis by FCM 
after the determination of the cell number. In some experiments, lymphocytes were 
collected from LNs of DO11.10 or DO11.10/CCR2-/- mice, which were untreated or 
intravenously administered with OVA as described above. The obtained cells were 
stained with 2 μM of CFSE (Life Technologies Corporation, Carlsbad, CA), and were 
transferred to WT mice (Supporting Information Figure 1A and B). 
 
Cell preparation 
Thymus, LN, and spleen were collected from 4 to 8-week old mice to obtain single cell 
suspensions by mechanical digestion. PBMCs were isolated from whole blood by using 
Histopaque-1083 reagent (Sigma Aldrich). The cells in the air pouch were collected as 
described above. 
 
Spelenectomy and thymectomy 
The spleen was exposed by an oblique incision, in the left upper abdominal quadrant 
while the animal was kept under anesthesia with Avertin (2, 2, 2-Tribromoethanol) 
(Sigma Aldrich). After the splenic arteries and venous vessels were cauterized to 
minimize blood loss, the spleen was removed. The thymus was mechanically removed 
through an incision in the neck and thoracic wall extending to the level of the second 
rib, while mice were kept under anesthesia with Avertin. Sham-treated animals 






Mice were subcutaneously immunized with 200 μg of OVA protein in 200 μl of the 
emulsion consisting of an equal volume of PBS and complete Freund’s adjuvant (CFA) 
(Sigma Aldrich). Ten days after the immunization, 100 μg of heat aggregated OVA in 
50 μl of PBS was injected into the footpad. 24 h after the footpad injection, footpad 
thickness was measured and the intensity of inflammation was histologically 
evaluated. 
 
Preparation of BM chimeric mice 
BM cells were obtained from DO11.10 and WT mice, and the resultant cells were 
mixed at the indicated ratio. After WT recipient mice were lethally irradiated (8 Gy), 
they received 1×107 BM cells intravenously. The experiments were conducted on the 
obtained BM chimeric mice more than three weeks after transplantation. 
 
In vivo transfection of tRANTES 
cDNA encoding mouse tRANTES (its nucleotide sequence described in Supporting 
Information Figure 6) was subcloned into the pLIVE expression plasmid vector (Mirus, 
Madison, WI). 10 g of the resultant or empty pLIVE expression plasmid vector was 
injected into mice by using TransIT®-EE Delivery Solution (Mirus) according to the 
manufacturer’s instructions, because this gene delivery system can sustain serum 




Mouse footpads were cut off and fixed in fixating agent, Yufix (Sakura Finetec Japan, 
Tokyo, Japan). After subsequent decalcification with formic acid (Nacalai Tesque, 
Kyoto, Japan), the samples were embedded with paraffin and sliced at 3 μm thickness. 
For Ag retrieval, the deparaffinized slides were autoclaved in 10 mmol/L citrate buffer 
(pH 6.0) for 10 min at 120 oC. After blocking with a protein block serum-free solution 
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(DAKO, Carpinteria, CA), anti-Foxp3 Ab (FJK-26s) was added to the tissue sections 
and incubated overnight in a humidified box at 4oC. Immune complexes were then 
detected using the CSA systems (DAKO) followed by staining with hematoxylin. 
 
Determination of chemokine concentrations 
Concentrations of MCP-1/CCL2, TARC/CCL17, MDC/CCL22, RANTES/CCL5 and 
SDF-1/CXCL12 in the air pouch fluid were determined by Quantikine ELISA kit 
(R&D systems) according to the manufacturer’s instructions. 
 
FCM 
Single cell suspensions were stained with various combinations of fluorescent 
dye-conjugated or non-conjugated specific Abs in magnetic-activated cell sorting 
buffer (PBS supplemented with 2 mM EDTA and 3 % FBS). For non-conjugated Abs, 
fluorescence-conjugated secondary Abs were used. Subsequently, the cells were fixed, 
permeabilized and stained with a Foxp3 staining set (eBioscience). Subsequently, the 
expression of each molecule was analyzed using FACSCanto II (BD Biosciences) with 
the help of FlowJo (TreeStar, Ashland, OR). 
 
Statistical analysis 
Data are represented as mean and SD. Statistical significance was determined by 
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Legends to Figures 
 
Figure 1. Preferential migration of Ag-specific Treg cells to the Ag-containing site 
(A) Schematic presentation of the experimental procedures of the air pouch model. (B) 
Infiltrating cells were collected from the air pouch at the indicated time points. After 
the cell numbers were determined, the cells were analyzed using FCM by gating on 
KJ1-26-high region. The absolute KJ1-26highFoxp3+ cell numbers as Treg-cell numbers 
(left), the absolute KJ1-26highFoxP3- cell numbers as Teff-cell numbers (middle), and 
the proportion of Foxp3+ and Foxp3- cells among KJ1-26high cells in the air pouch 
(right) are shown. Data are shown as mean +SD of 5 samples pooled from 2 
experiments. **p < 0.01, one-way ANOVA followed by Tukey-Kramer test. (C) 
DO11.10 mice were treated with the air pouch protocol and additionally, 100 μg of 
OVA or BSA in 1 ml of PBS was injected into the air pouch. 24 h after the injection, 
the cells were obtained from the air pouch. Air pouch-infiltrating cells were analyzed 
by gating on KJ1-26-high region, and data are shown as mean + SD of 5 samples 
pooled from 2 independent experiments. *p < 0.05, Student’s t-test. (D) Lymphocytes 
were obtained from DO11.10 mice, which were immunized or non-immunized with the 
protocol shown in Supporting Information Figure 1A. The resultant cells were labeled 
with CFSE and were transferred into WT mice. Thereafter, 100 μg of OVA in 1 ml of 
PBS was injected into the air pouch of WT mice. 72 h after the injection, the cells were 
obtained from air pouch or axillary LNs (dLN). The total cells in the air pouch and 
dLNs were analyzed on Foxp3 and CFSE by gating on KJ1-26-high region, and 
representative results from 3 independent experiments are shown. 
 
Figure 2. Intravenous OVA injection-induced Treg-cell expansion in thymus 
(A) OVA was intravenously injected twice on Day 0 and Day 1 into DO11.10 mice.  
Thymus was collected on Day 0, Day 3 and Day 5. After the cell numbers were 
determined, the resultant thymocytes were analyzed for the expression of KJ1-26 and 
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Foxp3 by using FCM and the absolute numbers of KJ1-26highFoxp3+ cells were 
calculated. The data are shown as mean + SD of 5 samples pooled from 2 independent 
experiments. **p < 0.01, one-way ANOVA followed by Tukey-Kramer test. (B) On Day 
5, PBMCs were obtained from DO11.10 mice, which were immunized twice with OVA. 
The total resultant cells were analyzed for the expression of CD25 and Foxp3 after 
gating on KJ1-26 high region by using FCM. As a control, PBMCs were obtained from 
untreated DO11.10 mice. The percentage of CD25highFoxp3+ or CD25lowFoxp3+ cells is 
shown in each panel. Representative results from 5 independent animals are shown. 
(C) Thymectomy, splenectomy or sham surgery was performed on DO11.10 mice. Two 
weeks after the operation, 2 mg of OVA was intravenously injected twice, on Day 0 
and Day 1. On Day 3, PBMCs were collected and analyzed by FCM. The fold change 
in Treg cells is shown as mean + SD of 4 samples pooled from 2 experiments. *p < 
0.05; N.S., not significant, Student’s t-test. (D) Total thymocytes or splenocytes 
collected on Day 0 or Day 3 were analyzed for Helios expression after gating on 
KJ1-26highFoxp3+ cells. Data are shown as mean + SD of 4 animals pooled from 2 
experiments. *p < 0.05; **p < 0.01, one-way ANOVA followed by Tukey-Kramer test. 
(E) Helios expression on KJ1-26highFoxp3+ cells (gray-filled histogram) or 
KJ1-26highFoxp3- cells (dashed-line histogram) from peripheral blood was analyzed by 
FCM, and representative results from 3 independent experiments are shown. The value 
shown indicates % positive cells among KJ1-26highFoxp3+ cells. (F) Peripheral 
lymphocytes, which were obtained from DO11.10 mice un-immunized or immunized 
with OVA, were administered to WT mice with air pouches. 2 mg of OVA was 
intravenously injected twice only into WT mice, which received unimmunized, naïve 
lymphocytes. Finally, 100 μg of OVA was further injected into the air pouch of WT 
mice receiving DO11.10 mouse-derived lymphocytes (Supporting Information Figure 
1B). The total cells in the air pouch were obtained to determine the proportion of 
Foxp3+ cells among KJ1-26high cells. Data are shown as mean + SD of 4 samples 




Figure 3. Ag-specific Treg-cell migration to the Ag-containing site in a CCR2- or 
CCR4-dependent manner 
(A) On Day 5 of the air pouch model, cells were obtained from the air pouch 
(gray-filled histograms) and the dLN (black line histograms) of DO11.10 mice. The 
cells were analyzed for the expression levels of chemokine receptors among 
KJ1-26highFoxp3+ Treg cells (top) and KJ1-26highFoxp3- Teff cells (bottom). Values 
shown indicate % positive cells among air pouch-infiltrating cells. Representative data 
from 5 independent experiments are shown. (B) DO11.10 or DO11.10/CCR2-/- mice 
were treated as shown in Figure 1A. The total cells were obtained on Day 5 from the 
air pouch and dLNs. The ratios of Foxp3+ cells among KJ1-26high cells (left), the 
absolute numbers of KJ1-26highFoxp3+ cells from air pouch (middle) and the ratio of 
KJ1-26highFoxp3+ cells from dLNs (right) were determined and shown as mean + SD of 
5 individual animals pooled from 2 experiments. *p < 0.05; **p < 0.01, Student’s t-test. 
(C) Lymphocytes were obtained from DO11.10 mice or DO11.10/CCR2-/-, which were 
immunized as shown in Supporting Information Figure 1A. The resultant cells were 
labeled with CFSE and were transferred into WT mice. Thereafter, 100 μg of OVA in 1 
ml of PBS was injected into the air pouch of WT mice. 72 h after the injection, the 
cells were obtained from air pouch or dLNs. The total cells in the air pouch and dLNs 
were analyzed for Foxp3 by gating on KJ1-26high and CFSE-positive region, and 
representative results from 3 independent experiments are shown. 
 
Figure 4. Combined administration of OVA and IL-2 ICs suppresses OVA-induced 
inflammation. 
(A) Schematic presentation of induction procedures of Ag-specific DTH reactions. (B) 
BM chimeric mice with about 15 % lymphocytes expressing KJ1-26 (Supporting 
Information Figure 8) were treated as in Figure 4A. Skin tissues were obtained on Day 
16 for histological evaluation using H&E staining. Representative results from 5 
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individual animals are shown; scale bar, 100 m. (C) Paw thickness was determined 
and the changes in thickness (Δmm) were calculated by subtracting the original 
thickness from the thickness of swollen paw. Data are shown as mean + SD of 5 
animals from a single experiment performed. **p < 0.01; N.S., not significant, one-way 
ANOVA followed by Tukey-Kramer test. (D) BM chimeric mice were immunized 
twice with 2 mg of OVA. Peripheral blood was obtained on Day 10 to determine the 
proportion of CD25highKJ1-26highFoxp3+ or CD25highV+Foxp3+ cells among 
lymphocytes, shown as mean ± SD of 5 animals from an experiment. Vα2 TCR was 
used as a marker of polyclonal Treg cells. **p < 0.01; N.S., not significant, Student’s 
t-test. (E) Skin tissues were obtained on Day 16. The tissues were stained with 
anti-Foxp3 Ab. The proportions of Foxp3+ cells among mononuclear cells were 
determined by using Image J and shown as mean +S D of 5 individual animals from a 
single experiment performed. **p < 0.01, one-way ANOVA followed by Tukey-Kramer 
test. 
 
Figure 5. Reversal of OVA and IL-2 ICs-induced suppression of DTH by blockade 
of CCR2. 
(A) DTH was elicited in BM chimeric mice, with 15% lymphocytes consisting of 
either DO11.10 or DO11.10/CCR2-/- lymphocytes. The tissues were obtained 1 day 
after OVA injection into the footpad and were processed to H&E staining. 
Representative results from 5 individual animals are shown; scale bar, 100 μm. (B) The 
changes in thickness (Δmm) were determined when the tissues were obtained shown in 
Figure 5A. Data are shown as mean + SD of 5 individual animals from a single 
experiment performed. (C) The same tissues used in Figure 5B were stained with 
anti-Foxp3 Ab. The proportions of Foxp3+ cells to mononuclear cells were determined 
by using Image J and shown as mean + SD of 5 individual animals from a single 





Figure 6. Combined IL-2 ICs and Ag treatment inhibits the DTH by efficient 
expansion of Ag-specific Treg cells. 
WT mice were treated intravenously with either IL-2 ICs, OVA alone or the 
combination of OVA and IL-2 ICs. Thereafter, DTH was elicited in WT mice as shown 
in Figure 4A. (A) Skin tissues were obtained on Day 16 and were stained with H&E for 
histological analysis. Representative results from 5 individual animals are shown; scale 
bar, 100 m. (B) Paw thickness on Day 16 was determined and shown as mean + SD 
were calculated of 5 individual from a single experiment performed. **p < 0.01; N.S., 
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Legends to Supplemental Figures 
S1. Nucleotide sequence of tRANTES 
The inserted tRANTES nucleotide sequence is shown. Blue and red sequence encodes 
RANTES signal peptide and 9-68 RANTES (mature peptide), respectively. 
 
S2. Gating strategy of Tregs and Teffs 
Cells were stained by KJ1-26 and Foxp3. The cells were gated on FSC/SSC for 
lymphocyte and further gated on KJ1-26highFoxp3+ cells for Tregs and 
KJ1-26highFoxp3-cells for Teffs. 
  
S3. Schematics presentation of adoptive transfer experiment 
(A) Lymphocytes were obtained from DO11.10 mice, which were untreated or injected 
twice with 2 mg of OVA. The obtained cells were labeled with CFSE and transferred to 
wild-type mice bearing the air pouch. Three days after OVA injection to air pouch, the 
cells were collected from the air pouch for the analysis with FCM. (B) Lymphocytes 
were obtained from DO11.10 and were transduced into another DO11.10 mouse after 
CFSE labeling. OVA was injected into air pouch with or without prior repeated 
intravenous OVA injection. Air pouch infiltrating cells were collected and analyzed by 
using FCM. 
 
S4. Expression of Foxp3 and KJ1-26 in thymocytes after intravenous OVA 
injection 
OVA was intravenously injected twice on Day 0 and Day 1 into DO11.10 mice.  
Thymocytes were collected on Day 0 and Day 3 and were analyzed by using FCM. 
Numbers in quadrants indicate the percentage of cells in the designated gate. 
Representative results from 5 independent experiments are shown here. 
 
S5. Alteration of KJ1-26highFoxp3- thymocytes after intravenous OVA injection 
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OVA was intravenously injected twice on Day 0 and Day 1 into DO11.10 mice. 
Thymus was collected on Day 0 and Day 3. After the cell numbers were determined, 
the resultant thymocytes were analyzed for the expression of KJ1-26 and Foxp3 by 
using FCM and the absolute numbers of KJ1-26highFoxp3- cells were calculated. The 
mean and SD from 5 independent experiments are shown here. Student’s t-test was 
used for statistical analysis. N.S., not significant. 
 
S6. Alteration of chemokine expression in the air pouch after OVA injection 
DO11.10 mice were treated as shown in Figure 1A. The fluids in the air pouch were 
obtained at the indicated time intervals after OVA injection into the air pouch. The 
concentrations of CCL2, CCL5, CCL17, and CCL22 in the air pouch were determined 
on 5 individual animals by using ELISA. Mean and SD were calculated from 5 
individual animals. Significant difference to control group are shown here. One-way 
ANOVA followed by Tukey-Kramer test was used for statistical analysis. *, p < 0.05; *, 
p < 0.01. 
 
S7. Effects of CCR4-signal blockade on the mobilization of OVA-specific Tregs 
DO11.10 mice were immunized twice with 2 mg of OVA on Day 1 and 2. On Day 4, 
100 μg of anti-CCL17 or anti-CCL22 Ab was intravenously injected 1 hr before OVA 
injection into the air pouch (Figure 1A). As a control, rat control IgG was injected. The 
cells were obtained on Day 5 from the air pouch and the draining lymph node to 
determine the proportion of KJ1-26highFoxp3+ cells. Proportion of Foxp3+ cells to 
KJ1-26high cells (left), the number of KJ1-26highFoxp3+ cells from air pouch (middle) 
and the proportion of Foxp3+ cells to KJ1-26high cells in draining lymph node (right) 
are shown. Mean and SD were calculated from 5 individual animals and are shown 
here. One-way ANOVA followed by Tukey-Kramer test was used for statistical 
analysis. *, p < 0.05; **, p < 0.01; N.S., not significant. 
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S8. Effects of CCR5-signal blockade on the mobilization of OVA-specific Tregs 
Ten g of pLIVE-tRANTES vector was in vivo transfected 5 days before air pouch 
formation. As a control, control pLIVE vector was transfected. DO11.10 mice were 
immunized twice with 2 mg of OVA on Day 0 and Day 1. OVA was injected into the air 
pouch on Day 4 (Figure 1A). The cells were obtained on Day 5 from air pouch and the 
draining lymph node to determine the proportion of KJ1-26highFoxp3+ cells. Proportion 
of Foxp3+ cells to KJ1-26high cells (left), the number of KJ1-26highFoxp3+ cells from air 
pouch (middle) and the proportion of Foxp3+ cells to KJ1-26high cells in the draining 
lymph node (right) are shown. Mean and SD were calculated from 3 individual animals 
and are shown here. Student’s t-test was used for statistical analysis. N.S., not 
significant. 
 
S9. Chimerism of DO11.10 TCR expressing T cells in BM chimera 
Peripheral blood was obtained from BM chimera to determine the proportion of 
KJ1-26high cells to CD4+ cells. Percentage of CD4+KJ1-26high and CD4+KJ1-26negative to 
low cells are shown. 
 
S10. Expansion of polyclonal Tregs by IL-2 IC treatment 
BM chimeric mice were daily injected with IL-2 IC for 3 days. Three days after the last 
IL-2 IC injection, expression of CD25 and Foxp3 on Vα2+ (upper panels) and 
KJ1-26high cells (lower panels) were observed. Percentage of CD25highFoxp3+ and 
CD25lowFoxp3+ cells are shown in each panel. 
 
S11. Effects of CCR4 blockade on antigen-induced immune reaction in DTH 
BM chimeric mice were treated with the protocol shown in Figure 4A. Anti-CCL17 
was intravenously injected 1 hr before OVA injection to footpad. As a control, rat-IgG 
was injected. Paw thickness were determined on 5 individual animals. The changes in 
thickness (Δmm) were calculated by subtracting the original thickness from the 
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thickness of swollen paw. Mean and SD were calculated from 5 individual animals and 
are shown here. One-way ANOVA followed by Tukey-Kramer test was used for 
statistical analysis. *, p < 0.05; **, p < 0.01; N.S., not significant. 


